A genetically engineered human Kunitz protease inhibitor with increased kallikrein inhibition in an ovine model of cardiopulmonary bypass

Abstract

A recombinant human serine protease inhibitor known as Kunitz protease inhibitor (KPI) wild type has functional similarities to the bovine Kunitz inhibitor, aprotinin, and had shown a potential to reduce bleeding in an ovine model of cardiopulmonary bypass (CPB). The aim of this study was to assess KPI-185, a modification of KPI-wild type that differs from KPI-wild type in two amino acid residues and which enhances anti-kallikrein activity in a further double-blind, randomized study in an ovine model of CPB, and to compare with our previous study of KPI-wild type and aprotinin in the same ovine model. Post-operative drain losses and subjective assessment of wound ‘dryness’ showed no significant differences between KPI-185 and KPI-wild type, despite the significant enhancement of kallikrein inhibition using KPI-185 seen in serial kallikrein inhibition assays.

These preliminary findings support the hypothesis that kallikrein inhibition is not the major mechanism by which Kunitz inhibitors such as aprotinin reduce perioperative bleeding.

Get full access to this article

View all access options for this article.

References

Segal H , Hunt BJ. Aprotinin: pharmacological reduction of perioperative bleeding . Lancet 2000; 355: 1289-1290 .

Masters CL , Simms G , Weinmann NA , Multhaup G , McDonald BL , Beyreuther K. Amyloid plaque core protein in Alzheimer’s disease and Down’s syndrome . Proc Natl Acad Sci USA 1985; 82: 4245-4249 .

Van Nostrand WE , Wagner SL , Suzuki M et al. Protease nexin-II, a potent anti-chymotrypsin, shows identity to amyloid -protein precursor . Nature 1989; 341: 546-547 .

Van Nostrand WE , Wagner SL , Farrow JS , Cunningham DD. Immunopurification and protease inhibitory properties of protease nexin-2/amyloid -protein precursor . J Biol Chem 1990; 265: 9591-9594 .

Smith RP , Higuchi DA , Broze GJ. Platelet coagulation factor XIa inhibitor, a form of Alzheimer amyloid precursor protein . Science 1990; 248: 1126-1128 .

Zhang Y , Scandura JM , Van Nostrand WE , Walsh PN. The mechanism by which heparin promotes the inhibition of coagulation factor XIa by protease nexin-2 . J Biol Chem 1997; 272: 26139-26144 .

Mahdi F , Van Nostrand WE , Schaimier AH. Protease nexin 2/amyloid beta-protein precursor inhibits factor Xa in the prothrombinase complex . J Biol Chem 1995; 270: 23468-23474 .

Ohri SK , Parratt R , Becket JM , Brannan J , Hunt BJ , Taylor KM. Genetically engineered serine protease inhibitor for haemostasis after cardiac operations . Ann Thorac Surg 1996; 61: 1223-1230 .

Machin SJ , Mackie IJ. An account of laboratory techniques. In: Chanarin I ed. Laboratory haematology. New York: Churchill Livingstone , 1989: 263-399.

10.

Wuthrich B , Schmid P , Schmid ER , Tornic M. IgE-mediated anaphylactic reaction to aprotinin during anaesthesia . Lancet 1992; 340: 173-174 .

11.

Schulze K , Graeter T , Schaps D , Hausen B. Severe anaphylactic shock due to repeated application of aprotinin in patients following intrathoracic aortic replacement . Eur J Cardiothorac Surg 1993; 7: 495-496 .

12.

Boisclair MD , Lane DA , Philippou H et al. Mechanism of thrombin generation during surgery and cardiopulmonary bypass . Blood 1993; 82: 3350-3357 .

13.

Parratt R , Hunt BJ. Direct activation of factor X by monocytes occurs during cardiopulmonary bypass . Br J Haematol 1998; 101: 40-46 .

14.

Ray MJ , Marsh NA. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin . Thromb Haemost 1997; 78: 1021-1026 .

15.

Blauhut B , Harringer W , Bettelheim P , Doran JE , Spath P , Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass . J Thorac Cardiovasc Surg 1994; 108: 1083-1091 .